Claire Lancaster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claire Lancaster has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Koychev
Imperial College London
5 shared publications - Jasmine Blane
Oxford Health NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
4 shared publications - Amy Chinner
School of Psychology, University of Birmingham, Edgbaston, UK
3 shared publications - Chris Hinds
University of Oxford, Oxford United Kingdom
3 shared publications Naji Tabet
Brighton & Sussex Medical School, Brighton, East Sussex United Kingdom
3 shared publicationsSam Berens
School of Psychology University of Sussex Brighton UK
3 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Development and usability testing of Co-Cog: a co-produced digital system for post-diagnostic monitoring of people living with dementia or mild cognitive impairment (Preprint)
BACKGROUND People living with dementia or mild cognitive impairment often experience limited access to structured post-diagnostic monitoring and support, particularly within community settings. Digital health technologies may help address these gaps by enabling ongoing monitoring of health, wellbeing, and cognitive function. However, many existing digital tools have limited accessibility and are insufficiently co-produced with people living with dementia, care partners, and healthcare professionals. OBJECTIVE This study aimed to co-produce and iteratively develop a digital monitoring system, Co-Cog, to support post-diagnostic monitoring of health, wellbeing, and cognition in people living with dementia or mild cognitive impairment, and to evaluate its usability and acceptability. METHODS A participatory co-production and usability design was employed between March 2022 and June 2024. The development process comprised three iterative phases: (1) stakeholder consultation and information gathering, (2) co-production and system development, and (3) pilot usability testing. Participants included people living with dementia or mild cognitive impairment, informal care partners, and dementia health and care professionals. Data were collected through interviews, focus groups, co-production workshops, feedback journals, and pilot testing interviews. Qualitative data were analysed iteratively using content-informed thematic approaches to identify priorities relating to accessibility, usability, monitoring domains, and implementation considerations. RESULTS Stakeholders identified substantial unmet needs in post-diagnostic monitoring and strongly supported the development of an accessible digital tool capable of facilitating ongoing support and earlier identification of health or wellbeing concerns. Co-production partners prioritised monitoring domains including mood, sleep, mobility, social engagement, medication management, sensory difficulties, continence, delirium symptoms, and care partner wellbeing. Accessibility and usability refinements included simplified language, pictorial response scales, auditory support features, streamlined navigation, dynamic question presentation, and gamified cognitive assessments. Pilot usability testing demonstrated overall acceptability and ease of use, although some participants reported barriers relating to installation and digital literacy. The first fully functional Co-Cog prototype incorporates two linked components: a patient- and care partner-facing smartphone app, and a workforce-facing interface that includes a red-amber-green triage system, intended to support future clinical integration. CONCLUSIONS This study demonstrates the feasibility of co-producing an accessible digital health system for post-diagnostic monitoring in dementia and mild cognitive impairment. Close collaboration with people living with dementia, care partners, and professionals was critical to ensuring usability, accessibility, and clinical relevance. Further research is required to evaluate longitudinal engagement, implementation within healthcare services, and psychometric and clinical validity.
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDevelopment and usability testing of Co-Cog: a co-produced digital system for post-diagnostic monitoring of people living with dementia or mild cognitive impairment (Preprint)
BACKGROUND People living with dementia or mild cognitive impairment often experience limited access to structured post-diagnostic monitoring and support, particularly within community settings. Digital health technologies may help address these gaps by enabling ongoing monitoring of health, wellbeing, and cognitive function. However, many existing digital tools have limited accessibility and are insufficiently co-produced with people living with dementia, care partners, and healthcare professionals. OBJECTIVE This study aimed to co-produce and iteratively develop a digital monitoring system, Co-Cog, to support post-diagnostic monitoring of health, wellbeing, and cognition in people living with dementia or mild cognitive impairment, and to evaluate its usability and acceptability. METHODS A participatory co-production and usability design was employed between March 2022 and June 2024. The development process comprised three iterative phases: (1) stakeholder consultation and information gathering, (2) co-production and system development, and (3) pilot usability testing. Participants included people living with dementia or mild cognitive impairment, informal care partners, and dementia health and care professionals. Data were collected through interviews, focus groups, co-production workshops, feedback journals, and pilot testing interviews. Qualitative data were analysed iteratively using content-informed thematic approaches to identify priorities relating to accessibility, usability, monitoring domains, and implementation considerations. RESULTS Stakeholders identified substantial unmet needs in post-diagnostic monitoring and strongly supported the development of an accessible digital tool capable of facilitating ongoing support and earlier identification of health or wellbeing concerns. Co-production partners prioritised monitoring domains including mood, sleep, mobility, social engagement, medication management, sensory difficulties, continence, delirium symptoms, and care partner wellbeing. Accessibility and usability refinements included simplified language, pictorial response scales, auditory support features, streamlined navigation, dynamic question presentation, and gamified cognitive assessments. Pilot usability testing demonstrated overall acceptability and ease of use, although some participants reported barriers relating to installation and digital literacy. The first fully functional Co-Cog prototype incorporates two linked components: a patient- and care partner-facing smartphone app, and a workforce-facing interface that includes a red-amber-green triage system, intended to support future clinical integration. CONCLUSIONS This study demonstrates the feasibility of co-producing an accessible digital health system for post-diagnostic monitoring in dementia and mild cognitive impairment. Close collaboration with people living with dementia, care partners, and professionals was critical to ensuring usability, accessibility, and clinical relevance. Further research is required to evaluate longitudinal engagement, implementation within healthcare services, and psychometric and clinical validity.
- Open Access
- 18 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
The Early Detection of Neurodegenerative diseases (EDoN) Initiative: protocol for a meta-cohort study (Preprint)
BACKGROUND Conventional diagnostic tests for dementia are invasive, expensive, and/or not scalable. Blood-based biomarkers are beginning to enter clinical practice but are not yet widely available, and do not currently provide differential-diagnostic information about non-Alzheimer’s disease pathologies. The Early Detection of Neurodegenerative diseases (EDoN) Initiative is investigating the potential utility of digital measures to support the early detection of dementia at scale. OBJECTIVE The ultimate objective is to evaluate the utility of the included wearables/apps as early detection markers for dementia. This will be achieved by analyzing relationships between wearables/apps and dementia outcomes, including both hard endpoints (i.e., clinical progression) as well as surrogate markers (e.g., cognitive decline). METHODS Four international cohorts (UK, Australia, USA) collected longitudinal digital, clinical and biomarker data from healthy controls and people at elevated risk of cognitive decline. Participants used ≥2 of the following wearables/apps: electroencephalographic sleep headband, wrist-worn activity tracker, cognitive testing smartphone app, and/or passive smartphone monitoring app. RESULTS Across the four cohorts, 436 individuals were enrolled, including 149 (34%) healthy controls, 166 (38%) patients with subjective cognitive decline (SCD), 114 (26%) patients with mild cognitive impairment, and 7 (2%) patients with very mild dementia. Fifty participants (11%) withdrew during the study, while 386 (89%) participants completed the study. CONCLUSIONS The harmonized EDoN data will be made available for sharing via a cloud-based trusted research environment, driving progress in the field.
- 18 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Early Detection of Neurodegenerative diseases (EDoN) Initiative: protocol for a meta-cohort study (Preprint)
BACKGROUND Conventional diagnostic tests for dementia are invasive, expensive, and/or not scalable. Blood-based biomarkers are beginning to enter clinical practice but are not yet widely available, and do not currently provide differential-diagnostic information about non-Alzheimer’s disease pathologies. The Early Detection of Neurodegenerative diseases (EDoN) Initiative is investigating the potential utility of digital measures to support the early detection of dementia at scale. OBJECTIVE The ultimate objective is to evaluate the utility of the included wearables/apps as early detection markers for dementia. This will be achieved by analyzing relationships between wearables/apps and dementia outcomes, including both hard endpoints (i.e., clinical progression) as well as surrogate markers (e.g., cognitive decline). METHODS Four international cohorts (UK, Australia, USA) collected longitudinal digital, clinical and biomarker data from healthy controls and people at elevated risk of cognitive decline. Participants used ≥2 of the following wearables/apps: electroencephalographic sleep headband, wrist-worn activity tracker, cognitive testing smartphone app, and/or passive smartphone monitoring app. RESULTS Across the four cohorts, 436 individuals were enrolled, including 149 (34%) healthy controls, 166 (38%) patients with subjective cognitive decline (SCD), 114 (26%) patients with mild cognitive impairment, and 7 (2%) patients with very mild dementia. Fifty participants (11%) withdrew during the study, while 386 (89%) participants completed the study. CONCLUSIONS The harmonized EDoN data will be made available for sharing via a cloud-based trusted research environment, driving progress in the field.
- Open Access
APOE-specific Cognitive Effects of Levetiracetam in Mid-Age Adults
Background: Low-dose levetiracetam is under investigation as a potential treatment for slowing Alzheimer’s Disease progression. This study tests whether levetiracetam enhances executive function in mid-age adults, and whether drug effects differ by Apolipoprotein e4 (APOE4+) genetic risk status. Methods: Fifty-eight adults (aged 45-65 years; 27 APOE33; 31 APOE4+) participated in a double-blind, placebo-controlled study of low-dose levetiracetam (125mg bidaily for two-weeks). At the end of each treatment phase, participants completed a switch-inhibition task. Results: Mid-age APOE4+ carriers were significantly slower and showed a greater cost of increasing executive demand than APOE33 individuals. Response times were quicker under levetiracetam, with increased benefits reported in APOE33 individuals, at younger ages, and in individuals with reduced levels of plasma-based biomarkers. Levetiracetam selectively benefitted accuracy in APOE33 individuals. Conclusion: Low-dose levetiracetam enhances executive function in midlife, particularly in individuals at lower risk of Alzheimer’s Disease based on age, APOE4 genotype, and proxies of neuropathology.
Open AccessAPOE-specific Cognitive Effects of Levetiracetam in Mid-Age Adults
Background: Low-dose levetiracetam is under investigation as a potential treatment for slowing Alzheimer’s Disease progression. This study tests whether levetiracetam enhances executive function in mid-age adults, and whether drug effects differ by Apolipoprotein e4 (APOE4+) genetic risk status. Methods: Fifty-eight adults (aged 45-65 years; 27 APOE33; 31 APOE4+) participated in a double-blind, placebo-controlled study of low-dose levetiracetam (125mg bidaily for two-weeks). At the end of each treatment phase, participants completed a switch-inhibition task. Results: Mid-age APOE4+ carriers were significantly slower and showed a greater cost of increasing executive demand than APOE33 individuals. Response times were quicker under levetiracetam, with increased benefits reported in APOE33 individuals, at younger ages, and in individuals with reduced levels of plasma-based biomarkers. Levetiracetam selectively benefitted accuracy in APOE33 individuals. Conclusion: Low-dose levetiracetam enhances executive function in midlife, particularly in individuals at lower risk of Alzheimer’s Disease based on age, APOE4 genotype, and proxies of neuropathology.
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e100799
APOE‐specific Cognitive Effects of Levetiracetam in Mid‐Age Adults
Background: Low‐dose levetiracetam is under investigation as a potential treatment for slowing the progression of Alzheimer’s Disease (AD). This commonly prescribed anti‐seizure medication has, at low doses, been shown to downregulate excess neuronal activity ‐ a prognostic risk marker observed in the earliest stages of AD, as well as in cognitively healthy carriers of the Apolipoprotein e4 (APOE4+) genetic risk variant. This study tests whether Levetiracetam has acute cognitive benefits in cognitively healthy mid‐age adults, including whether drug effects differ by APOE4 genotype. Methods: Fifty‐eight adults (aged 45‐65 years old; 27 APOE33; 31 APOE4+) participated in a double‐blind, placebo‐controlled study of low‐dose levetiracetam (125mg bidaily for two‐weeks). At the end of each treatment phase (placebo, levetiracetam), participants completed an executive switch‐inhibition task. Trial‐level data was subject to generalised linear mixed effect modelling to estimate drug by genotype group differences in probability of correct response and response time (RT). Results: Independent of the effect of treatment, APOE4+ carriers showed poorer accuracy on trials requiring response inhibition (F(1, 15935)=12.39, p <.001), and slower RTs across all task trials (F(1, 15107)=12.15, p <.001). A significant interaction between drug condition and APOE4 status was reported for both probability of correct response (F(1, 15935)=32.19, p <.001) and RT (F1, 15107) = 25.64, p <.001). Levetiracetam treatment significantly enhanced performance accuracy ( z‐ratio = ‐3.05, p =.002) and RT ( z‐ratio = 7.98, p <.001) in APOE33 individuals, with greater beneficial effects of Levetiracetam on response speed observed with lower age. Levetiracetam treatment did not significantly affect probability of correct response or RT in APOE4+ individuals ( p >.05). Conclusion: Low‐dose levetiracetam selectively enhanced executive function in mid‐age APOE33 individuals, but did not modify performance in APOE4+ carriers, despite literature reporting brain hyperactivity in this at‐risk group. Consistent with existing findings that an 18‐month intervention with low‐dose levetiracetam slows cognitive decline and brain atrophy in non‐APOE4+ individuals with Mild Cognitive Impairment due to AD, this drug may be used prophylactically in those who don’t carry an APOE4 risk variant. Ongoing future work must verify whether Levetiracetam modifies brain hyperactivity in APOE4+ individuals, and if so, what are the longer‐term cognitive and neurological consequences of this intervention.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e100799
Open AccessAPOE‐specific Cognitive Effects of Levetiracetam in Mid‐Age Adults
Background: Low‐dose levetiracetam is under investigation as a potential treatment for slowing the progression of Alzheimer’s Disease (AD). This commonly prescribed anti‐seizure medication has, at low doses, been shown to downregulate excess neuronal activity ‐ a prognostic risk marker observed in the earliest stages of AD, as well as in cognitively healthy carriers of the Apolipoprotein e4 (APOE4+) genetic risk variant. This study tests whether Levetiracetam has acute cognitive benefits in cognitively healthy mid‐age adults, including whether drug effects differ by APOE4 genotype. Methods: Fifty‐eight adults (aged 45‐65 years old; 27 APOE33; 31 APOE4+) participated in a double‐blind, placebo‐controlled study of low‐dose levetiracetam (125mg bidaily for two‐weeks). At the end of each treatment phase (placebo, levetiracetam), participants completed an executive switch‐inhibition task. Trial‐level data was subject to generalised linear mixed effect modelling to estimate drug by genotype group differences in probability of correct response and response time (RT). Results: Independent of the effect of treatment, APOE4+ carriers showed poorer accuracy on trials requiring response inhibition (F(1, 15935)=12.39, p <.001), and slower RTs across all task trials (F(1, 15107)=12.15, p <.001). A significant interaction between drug condition and APOE4 status was reported for both probability of correct response (F(1, 15935)=32.19, p <.001) and RT (F1, 15107) = 25.64, p <.001). Levetiracetam treatment significantly enhanced performance accuracy ( z‐ratio = ‐3.05, p =.002) and RT ( z‐ratio = 7.98, p <.001) in APOE33 individuals, with greater beneficial effects of Levetiracetam on response speed observed with lower age. Levetiracetam treatment did not significantly affect probability of correct response or RT in APOE4+ individuals ( p >.05). Conclusion: Low‐dose levetiracetam selectively enhanced executive function in mid‐age APOE33 individuals, but did not modify performance in APOE4+ carriers, despite literature reporting brain hyperactivity in this at‐risk group. Consistent with existing findings that an 18‐month intervention with low‐dose levetiracetam slows cognitive decline and brain atrophy in non‐APOE4+ individuals with Mild Cognitive Impairment due to AD, this drug may be used prophylactically in those who don’t carry an APOE4 risk variant. Ongoing future work must verify whether Levetiracetam modifies brain hyperactivity in APOE4+ individuals, and if so, what are the longer‐term cognitive and neurological consequences of this intervention.
- Open Access
- 10 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70246
Perceptual discrimination of complex objects: Apolipoprotein E e4 gene‐dose effects in mid‐life
INTRODUCTION: Complex perceptual discrimination is supported by tau‐vulnerable regions of the medial temporal lobe (MTL); notably the perirhinal cortex. This research tests whether there is a gene‐dose effect of apolipoprotein E (APOE) e4 on perceptual discrimination in mid‐life.METHODS: Three hundred and thirteen adults (45–65 years; grouped by APOE e4 gene‐dose (142 APOE33, 135 APOE34, 36 APOE44)) completed a Greebles “odd‐one‐out” task.RESULTS: APOE44 carriers were significantly less accurate in their perceptual judgments than APOE33 and APOE34 individuals. There was a significant Age x APOE e4 gene‐dose interaction in response speed, with the slope of age‐related slowing increasing stepwise with the number of e4 alleles carried. Estimates suggest high‐risk individuals are quicker than the APOE33 control group until age 54, but slower thereafter.DISCUSSION: Perceptual disadvantages specific to APOE44 individuals suggest this high‐risk group show compromised MTL function by mid‐life, potentially through accelerated tau‐aggregation. Task performance in APOE34 carriers is relatively preserved in mid‐life.Highlights: APOE44 carriers show impaired perceptual discrimination in mid‐age. APOE34 carriers show preserved perceptual discrimination in mid‐age. Age‐related slowing of perceptual judgments increases with APOE e4 gene‐dose. Perceptual discrimination tasks may be a valuable early marker of AD risk.
- 10 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70246
Open AccessPerceptual discrimination of complex objects: Apolipoprotein E e4 gene‐dose effects in mid‐life
INTRODUCTION: Complex perceptual discrimination is supported by tau‐vulnerable regions of the medial temporal lobe (MTL); notably the perirhinal cortex. This research tests whether there is a gene‐dose effect of apolipoprotein E (APOE) e4 on perceptual discrimination in mid‐life.METHODS: Three hundred and thirteen adults (45–65 years; grouped by APOE e4 gene‐dose (142 APOE33, 135 APOE34, 36 APOE44)) completed a Greebles “odd‐one‐out” task.RESULTS: APOE44 carriers were significantly less accurate in their perceptual judgments than APOE33 and APOE34 individuals. There was a significant Age x APOE e4 gene‐dose interaction in response speed, with the slope of age‐related slowing increasing stepwise with the number of e4 alleles carried. Estimates suggest high‐risk individuals are quicker than the APOE33 control group until age 54, but slower thereafter.DISCUSSION: Perceptual disadvantages specific to APOE44 individuals suggest this high‐risk group show compromised MTL function by mid‐life, potentially through accelerated tau‐aggregation. Task performance in APOE34 carriers is relatively preserved in mid‐life.Highlights: APOE44 carriers show impaired perceptual discrimination in mid‐age. APOE34 carriers show preserved perceptual discrimination in mid‐age. Age‐related slowing of perceptual judgments increases with APOE e4 gene‐dose. Perceptual discrimination tasks may be a valuable early marker of AD risk.
- Open Access
- 9 January 2025
- Vol. 20 (Suppl 8)
Do the effects of Hormone Replacement Therapy during menopause differ by APOE genotype?
Reported effects of Hormone Replacement Therapy (HRT) on late‐life neurodegenerative disease are inconsistent. Variability in the timing and formulation of HRT, plus whether an individual carries an Apolipoprotein (APOE) e4 genetic risk variant for Alzheimer’s Disease (AD), likely contribute to conflicting results. Additionally, whilst many studies have focused exclusively on the effects of exogenous oestrogen, the inclusion of testosterone in HRT appears protective against AD pathology, specifically in APOE e4 carriers. This project will investigate whether the introduction of HRT affects cognition in mid‐life, including whether benefits are influenced by HRT formulation, timing of initiation, and APOE genotype. Peri and early postmenopausal women (minimum n = 500) being newly prescribed HRT will be recruited from Newson Health specialist menopause clinics. Participants will complete a suite of online cognitive tasks targeting domains sensitive to preclinical AD (e.g., perceptual discrimination, spatial navigation), alongside questionnaires capturing cognitive, physical, and behavioural menopause symptoms, at baseline, 4‐months, and 12‐months. A tissue sample will be collected for APOE genotype analysis. HRT prescription and circulating blood‐hormone levels will also be available from clinic records. Existing cohort data (n = 10,222) from Newson Health indicates 97% patients present at clinic with memory or concentration complaints. Pilot data for this study (n = 85, mean age 56.48 years, peri/postmenopausal women) showed HRT users (relative to non‐users) were significantly quicker on a perceptual 'odd‐one‐out’ task (p = .025) and trended to show better lure discrimination on an object mnemonic similarity task (p = .064). This project builds on this by testing whether the introduction of HRT influences cognition longitudinally, including whether effects differ by HRT formulation (estrogen/+progesterone/+testosterone), timing of initiation relative to menopause, and APOE genotype. Exploratory analysis will consider whether predicted benefits of HRT are moderated by non‐cognitive menopause symptoms, cardiovascular health, and wider lifestyle factors. Exploring the impact of HRT on cognition, specifically in interaction with the leading genetic risk factor for AD, will further research into how we can promote women’s brain health from mid‐life. Additionally, this research will inform best‐practices for HRT prescription, considering possible effects on late‐life neurodegenerative disease.
- 9 January 2025
- Vol. 20 (Suppl 8)
Open AccessDo the effects of Hormone Replacement Therapy during menopause differ by APOE genotype?
Reported effects of Hormone Replacement Therapy (HRT) on late‐life neurodegenerative disease are inconsistent. Variability in the timing and formulation of HRT, plus whether an individual carries an Apolipoprotein (APOE) e4 genetic risk variant for Alzheimer’s Disease (AD), likely contribute to conflicting results. Additionally, whilst many studies have focused exclusively on the effects of exogenous oestrogen, the inclusion of testosterone in HRT appears protective against AD pathology, specifically in APOE e4 carriers. This project will investigate whether the introduction of HRT affects cognition in mid‐life, including whether benefits are influenced by HRT formulation, timing of initiation, and APOE genotype. Peri and early postmenopausal women (minimum n = 500) being newly prescribed HRT will be recruited from Newson Health specialist menopause clinics. Participants will complete a suite of online cognitive tasks targeting domains sensitive to preclinical AD (e.g., perceptual discrimination, spatial navigation), alongside questionnaires capturing cognitive, physical, and behavioural menopause symptoms, at baseline, 4‐months, and 12‐months. A tissue sample will be collected for APOE genotype analysis. HRT prescription and circulating blood‐hormone levels will also be available from clinic records. Existing cohort data (n = 10,222) from Newson Health indicates 97% patients present at clinic with memory or concentration complaints. Pilot data for this study (n = 85, mean age 56.48 years, peri/postmenopausal women) showed HRT users (relative to non‐users) were significantly quicker on a perceptual 'odd‐one‐out’ task (p = .025) and trended to show better lure discrimination on an object mnemonic similarity task (p = .064). This project builds on this by testing whether the introduction of HRT influences cognition longitudinally, including whether effects differ by HRT formulation (estrogen/+progesterone/+testosterone), timing of initiation relative to menopause, and APOE genotype. Exploratory analysis will consider whether predicted benefits of HRT are moderated by non‐cognitive menopause symptoms, cardiovascular health, and wider lifestyle factors. Exploring the impact of HRT on cognition, specifically in interaction with the leading genetic risk factor for AD, will further research into how we can promote women’s brain health from mid‐life. Additionally, this research will inform best‐practices for HRT prescription, considering possible effects on late‐life neurodegenerative disease.
- Open Access
- 9 January 2025
- Vol. 20 (Suppl 8)
Perceptual Discrimination of Complex Objects: Gene‐dose effects of APOE e4 in mid‐life
The perirhinal cortex is vulnerable to early phosphorylated tau (p‐tau) accumulation; deterioration of this region in the prodromal stages of Alzheimer’s Disease (AD) is associated with impaired ‘complex’ perceptual discrimination. This research examined whether there is a disadvantageous gene‐dose effect of Apolipoprotein (APOE) e4 on perceptual discrimination in mid‐life, facilitating greater understanding of how and when the deleterious effects of this variant emerge. Three‐hundred and thirteen mid‐aged adults (45‐65 years; 51% female; recruited by NIHR BioResource) completed a Greebles ‘odd‐one‐out’ task. Participants were grouped by APOE e4 gene‐dose (142 APOE33 controls, 135 APOE34, 36 APOE44). Frequentist and Bayesian Generalised Linear Mixed Effect Models probed genotype differences in probability and speed of correct perceptual discrimination, including in interaction with age. A significant non‐linear effect of APOE e4 gene dose was reported on probability of correct perceptual discrimination (F = 3.75, p = .25, Bayesian 95% Credibility Intervals (CI) = [.07, 1.90], driven by APOE44 performing worse than APOE33 controls and APOE34 carriers (Figure 1). In addition, there was a significant Age x APOE e4 gene‐dose interaction (F = 9.75, p = .002, Bayesian 95% CIs = [.00, .61]), with the slope of age‐related slowing increasing as a function of the number of e4 alleles carried (Figure 2). Estimates suggest high‐risk individuals are quicker than the APOE33 control group until age 54, but slower after age 60. Observed disadvantageous effects of APOE e4 on a perirhinal‐dependent perceptual discrimination task may indicate this region is prematurely compromised in carriers of this genetic risk variant, potentially through its influence on rate of p‐tau aggregation. These results highlight the utility of perceptual discrimination tasks as a sensitive, scalable marker of increased risk for neurodegenerative disease.
- 9 January 2025
- Vol. 20 (Suppl 8)
Open AccessPerceptual Discrimination of Complex Objects: Gene‐dose effects of APOE e4 in mid‐life
The perirhinal cortex is vulnerable to early phosphorylated tau (p‐tau) accumulation; deterioration of this region in the prodromal stages of Alzheimer’s Disease (AD) is associated with impaired ‘complex’ perceptual discrimination. This research examined whether there is a disadvantageous gene‐dose effect of Apolipoprotein (APOE) e4 on perceptual discrimination in mid‐life, facilitating greater understanding of how and when the deleterious effects of this variant emerge. Three‐hundred and thirteen mid‐aged adults (45‐65 years; 51% female; recruited by NIHR BioResource) completed a Greebles ‘odd‐one‐out’ task. Participants were grouped by APOE e4 gene‐dose (142 APOE33 controls, 135 APOE34, 36 APOE44). Frequentist and Bayesian Generalised Linear Mixed Effect Models probed genotype differences in probability and speed of correct perceptual discrimination, including in interaction with age. A significant non‐linear effect of APOE e4 gene dose was reported on probability of correct perceptual discrimination (F = 3.75, p = .25, Bayesian 95% Credibility Intervals (CI) = [.07, 1.90], driven by APOE44 performing worse than APOE33 controls and APOE34 carriers (Figure 1). In addition, there was a significant Age x APOE e4 gene‐dose interaction (F = 9.75, p = .002, Bayesian 95% CIs = [.00, .61]), with the slope of age‐related slowing increasing as a function of the number of e4 alleles carried (Figure 2). Estimates suggest high‐risk individuals are quicker than the APOE33 control group until age 54, but slower after age 60. Observed disadvantageous effects of APOE e4 on a perirhinal‐dependent perceptual discrimination task may indicate this region is prematurely compromised in carriers of this genetic risk variant, potentially through its influence on rate of p‐tau aggregation. These results highlight the utility of perceptual discrimination tasks as a sensitive, scalable marker of increased risk for neurodegenerative disease.
- Open Access
Perceptual discrimination of complex objects: APOE e4 gene-dose effects in mid-life
INTRODUCTION: Complex perceptual discrimination is supported by tau-vulnerable regions of the medial temporal lobe; notably the perirhinal cortex. This research tests whether there is a gene-dose effect of Apolipoprotein e4 on perceptual discrimination in mid-life. METHODS: 313 adults (45-65 years; grouped by APOE e4 gene-dose (142 APOE33, 135 APOE34, 36 APOE44)) completed a Greebles ‘odd-one-out’ task. RESULTS: APOE44 carriers were significantly less accurate in their perceptual judgements than APOE33 and APOE34 individuals. There was a significant Age x APOE e4 gene-dose interaction in response speed, with the slope of age-related slowing increasing stepwise with the number of e4 alleles carried. Estimates suggest high-risk individuals are quicker than the APOE33 control group until age 54, but slower thereafter. DISCUSSION: Perceptual disadvantages specific to APOE44 individuals suggest this high-risk group show compromised MTL-function by mid-life, potentially through accelerated tau-aggregation. Task performance in APOE34 carriers is relatively preserved across the studied age range. Research in Context: Systematic review: A review of the literature (e.g., PubMed; Google Scholar databases) revealed perceptual discrimination is impaired in the mild to moderate stages of Alzheimer’s Disease. No prior study, however, tests for an effect of APOE e4 gene-dose in healthy adulthood. Interpretation: Homozygous carriers of an APOE e4 genetic risk variant show perceptual disadvantages in mid-life. This may possibly reflect compromised MTL-function in this group, consistent with the theory perceptual discrimination will be vulnerable to early transentorhinal tau-accumulation. There is limited evidence of impairment in individuals carrying one copy of APOE e4 in mid-life. Future directions: Whether transentorhinal and hippocampal tau mediates the relationship between APOE e4 gene-dose and perceptual discrimination remains to be established. Future research may also explore the utility of perceptual discrimination tasks in clinical trials targeting the preclinical stages of Alzheimer’s Disease.
Open AccessPerceptual discrimination of complex objects: APOE e4 gene-dose effects in mid-life
INTRODUCTION: Complex perceptual discrimination is supported by tau-vulnerable regions of the medial temporal lobe; notably the perirhinal cortex. This research tests whether there is a gene-dose effect of Apolipoprotein e4 on perceptual discrimination in mid-life. METHODS: 313 adults (45-65 years; grouped by APOE e4 gene-dose (142 APOE33, 135 APOE34, 36 APOE44)) completed a Greebles ‘odd-one-out’ task. RESULTS: APOE44 carriers were significantly less accurate in their perceptual judgements than APOE33 and APOE34 individuals. There was a significant Age x APOE e4 gene-dose interaction in response speed, with the slope of age-related slowing increasing stepwise with the number of e4 alleles carried. Estimates suggest high-risk individuals are quicker than the APOE33 control group until age 54, but slower thereafter. DISCUSSION: Perceptual disadvantages specific to APOE44 individuals suggest this high-risk group show compromised MTL-function by mid-life, potentially through accelerated tau-aggregation. Task performance in APOE34 carriers is relatively preserved across the studied age range. Research in Context: Systematic review: A review of the literature (e.g., PubMed; Google Scholar databases) revealed perceptual discrimination is impaired in the mild to moderate stages of Alzheimer’s Disease. No prior study, however, tests for an effect of APOE e4 gene-dose in healthy adulthood. Interpretation: Homozygous carriers of an APOE e4 genetic risk variant show perceptual disadvantages in mid-life. This may possibly reflect compromised MTL-function in this group, consistent with the theory perceptual discrimination will be vulnerable to early transentorhinal tau-accumulation. There is limited evidence of impairment in individuals carrying one copy of APOE e4 in mid-life. Future directions: Whether transentorhinal and hippocampal tau mediates the relationship between APOE e4 gene-dose and perceptual discrimination remains to be established. Future research may also explore the utility of perceptual discrimination tasks in clinical trials targeting the preclinical stages of Alzheimer’s Disease.
- Open Access
- 2 April 2020
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 8 (4) , e16142
Evaluating the Feasibility of Frequent Cognitive Assessment Using the Mezurio Smartphone App: Observational and Interview Study in Adults With Elevated Dementia Risk
Background: By enabling frequent, sensitive, and economic remote assessment, smartphones will facilitate the detection of early cognitive decline at scale. Previous studies have sustained participant engagement with remote cognitive assessment over a week; extending this to a period of 1 month clearly provides a greater opportunity for measurement. However, as study durations are increased, the need to understand how participant burden and scientific value might be optimally balanced also increases. Objective: This study explored the little but often approach to assessment employed by the Mezurio app when prompting participants to interact every day for over a month. Specifically, this study aimed to understand whether this extended duration of remote study is feasible, and which factors promote sustained participant engagement over such periods. Methods: A total of 35 adults (aged 40-59 years) with no diagnosis of cognitive impairment were prompted to interact with the Mezurio smartphone app platform for up to 36 days, completing short, daily episodic memory tasks in addition to optional executive function and language tests. A subset (n=20) of participants completed semistructured interviews focused on their experience of using the app. Results: Participants complied with 80% of the daily learning tasks scheduled for subsequent tests of episodic memory, with 88% of participants still actively engaged by the final task. A thematic analysis of the participants’ experiences highlighted schedule flexibility, a clear user interface, and performance feedback as important considerations for engagement with remote digital assessment. Conclusions: Despite the extended study duration, participants demonstrated high compliance with the schedule of daily learning tasks and were extremely positive about their experiences. Long durations of remote digital interaction are therefore definitely feasible but only when careful attention is paid to the design of the users’ experience.
- 2 April 2020
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 8 (4) , e16142
Open AccessEvaluating the Feasibility of Frequent Cognitive Assessment Using the Mezurio Smartphone App: Observational and Interview Study in Adults With Elevated Dementia Risk
Background: By enabling frequent, sensitive, and economic remote assessment, smartphones will facilitate the detection of early cognitive decline at scale. Previous studies have sustained participant engagement with remote cognitive assessment over a week; extending this to a period of 1 month clearly provides a greater opportunity for measurement. However, as study durations are increased, the need to understand how participant burden and scientific value might be optimally balanced also increases. Objective: This study explored the little but often approach to assessment employed by the Mezurio app when prompting participants to interact every day for over a month. Specifically, this study aimed to understand whether this extended duration of remote study is feasible, and which factors promote sustained participant engagement over such periods. Methods: A total of 35 adults (aged 40-59 years) with no diagnosis of cognitive impairment were prompted to interact with the Mezurio smartphone app platform for up to 36 days, completing short, daily episodic memory tasks in addition to optional executive function and language tests. A subset (n=20) of participants completed semistructured interviews focused on their experience of using the app. Results: Participants complied with 80% of the daily learning tasks scheduled for subsequent tests of episodic memory, with 88% of participants still actively engaged by the final task. A thematic analysis of the participants’ experiences highlighted schedule flexibility, a clear user interface, and performance feedback as important considerations for engagement with remote digital assessment. Conclusions: Despite the extended study duration, participants demonstrated high compliance with the schedule of daily learning tasks and were extremely positive about their experiences. Long durations of remote digital interaction are therefore definitely feasible but only when careful attention is paid to the design of the users’ experience.
- 24 January 2020
- Published by Taylor & Francis in Journal of Clinical and Experimental Neuropsychology
- Vol. 42 (4) , 329-343
Gallery Game: Smartphone-based assessment of long-term memory in adults at risk of Alzheimer’s disease
Introduction: Gallery Game, deployed within the Mezurio smartphone app, targets the processes of episodic memory hypothesized to be first vulnerable to neurofibrillary tau-related degeneration in Alzheimer’s Disease, prioritizing both perirhinal and entorhinal cortex/hippocampal demands. Methods: Thirty-five healthy adults (aged 40–59 years), biased toward those at elevated familial risk of dementia, completed daily Gallery Game tasks for a month. Assessments consisted of cross-modal paired-associate learning, with subsequent tests of recognition and free recall following delays ranging from one to 13 days. Results: Retention intervals of at least three days were needed to evidence significant forgetting at both recognition and paired-associate recall test. The association between Gallery Game outcomes and established in-clinic memory assessments were small but numerically in the anticipated direction. In addition, there was preliminary support for utilizing the perirhinal-dependent pattern of semantic false alarms during object recognition as a marker of early impairment. Conclusions: These results support the need for tests of longer-term memory to sensitively record behavioral differences in adults with no diagnosis of cognitive impairment. Aggregate behavioral outcomes promote Gallery Game’s utility as a digital assessment of episodic memory, aligning with established theoretical models of object memory and showing small yet uniform associations with existing in-clinic tests. Initial support for the discriminatory value of perirhinal-targeted outcomes justifies ongoing large-sample validation against traditional biomarkers of Alzheimer’s disease.
- 24 January 2020
- Published by Taylor & Francis in Journal of Clinical and Experimental Neuropsychology
- Vol. 42 (4) , 329-343
Gallery Game: Smartphone-based assessment of long-term memory in adults at risk of Alzheimer’s disease
Introduction: Gallery Game, deployed within the Mezurio smartphone app, targets the processes of episodic memory hypothesized to be first vulnerable to neurofibrillary tau-related degeneration in Alzheimer’s Disease, prioritizing both perirhinal and entorhinal cortex/hippocampal demands. Methods: Thirty-five healthy adults (aged 40–59 years), biased toward those at elevated familial risk of dementia, completed daily Gallery Game tasks for a month. Assessments consisted of cross-modal paired-associate learning, with subsequent tests of recognition and free recall following delays ranging from one to 13 days. Results: Retention intervals of at least three days were needed to evidence significant forgetting at both recognition and paired-associate recall test. The association between Gallery Game outcomes and established in-clinic memory assessments were small but numerically in the anticipated direction. In addition, there was preliminary support for utilizing the perirhinal-dependent pattern of semantic false alarms during object recognition as a marker of early impairment. Conclusions: These results support the need for tests of longer-term memory to sensitively record behavioral differences in adults with no diagnosis of cognitive impairment. Aggregate behavioral outcomes promote Gallery Game’s utility as a digital assessment of episodic memory, aligning with established theoretical models of object memory and showing small yet uniform associations with existing in-clinic tests. Initial support for the discriminatory value of perirhinal-targeted outcomes justifies ongoing large-sample validation against traditional biomarkers of Alzheimer’s disease.